Physician profile
Hernan Zarate
NPI 1528275518
$5,212.43
in general payments reported to CMS, 2019-2025
19 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $491 · 2021: $201 · 2022: $602 · 2023: $1,234 · 2024: $1,606 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,777 · Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,777.10 |
| Food and Beverage | $1,436.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,966.79 | 2023-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $819.48 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $629.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.02 | 2019-2025 | Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $279.34 | 2019-2023 | |
| Genzyme Corporation | $264.48 | 2019-2025 | |
| Grifols USA, LLC | $186.78 | 2019-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $108.82 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $95.04 | 2019-2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $83.31 | 2019 | |
| Inspire Medical Systems, INC. | $80.48 | 2023 | Inspire |
| Genentech USA, INC. | $62.34 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $53.86 | 2023 | Zerbaxa, Dificid, Recarbrio |
| United Therapeutics Corporation | $44.57 | 2020 | |
| Allergan, INC. | $40.30 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $24.55 | 2020 | |
| Vifor Pharma, INC. | $23.55 | 2024 | Zemaira |
| Amgen INC. | $21.10 | 2022 | |
| Baxter Healthcare | $19.32 | 2024 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernan Zarate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.